Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management

Journal of Hepatology

Volumn 44, Issue SUPPL. 1, 2006, Pages

  Mauss, Stefan ^a  

^a Center for HIV and Hepatogastroenterology   (Germany)

Author keywords

Adverse events; Coinfection; Hepatitis; HIV; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ADEFOVIR; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE; CITALOPRAM; CYTOSINE; DICLOFENAC; DIDANOSINE; DOXEPIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIDOVUDINE;

ABSCESS; ANEMIA; ASTHENIA; CONFERENCE PAPER; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LACTIC ACIDOSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SUICIDE ATTEMPT; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 30144444473     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.11.024     Document Type: Conference Paper

References (43)

1. V. Di Martino, T. Thevenot, J.F. Colin, N. Boyer, M. Martinot, and F. Degos Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B Gastroenterology 123 2002 1812 1822
2. D.K. Wong, C. Yim, C.D. Naylor, E. Chen, M. Sherman, and S. Vas Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population Gastroenterology 108 1995 165 171
3. H. Zylberberg, J. Jiang, G. Pialoux, F. Driss, F. Carnot, and F. Dubois Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients Gastroenterol Clin Biol 20 1996 968 971
4. Y. Benhamou, C. Katlama, F. Lunel, A. Coutellier, E. Dohin, and N. Hamm The effects of lamivudine on replication of hepatitis B virus in HIV-infected men Ann Intern Med 125 1996 705 712
5. G.J. Dore, D.A. Cooper, C. Barrett, L.E. Goh, B. Thakrar, and M. Atkins Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-co-infected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee J Infect Dis 180 1999 607 613
6. P. Honkoop, R.A. de Man, H.G. Niesters, P.E. Zondervan, and S.W. Schalm Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy Hepatology 32 2000 635 639
7. W. Petry, O. Adams, and D. Haussinger Fatal hepatitis B reinfection after orthotopic liver transplantation in an HBsAg negative patient following withdrawal of lamivudine J Hepatol 33 2000 514 515
8. M. Bonacini, A. Kurz, S. Locarnini, A. Ayres, and C. Gibbs Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient co-infected with HIV Gastroenterology 122 2002 244 245
9. Y. Benhamou, M. Bochet, V. Thibault, V. Calvez, M.H. Fievet, and P. Vig Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus Lancet 358 2001 718 723
10. Y. Benhamou, M. Bochet, V. Thibault, V. Calvez, M.H. Fievet, and P. Vig Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients J Hepatol 36 2002 138
11. H. Hannon, C.I. Bagnis, Y. Benhamou, H. Beaufils, M. Sullivan, and C. Brosgart The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV Nephrol Dial Transplant 19 2004 386 390
12. C. Delaugerre, A.G. Marcelin, V. Thibault, G. Peytavin, T. Bombled, and M.V. Bochet Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-co-infected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine Antimicrob Agents Chemother 46 2002 1586 1588
13. Y. Benhamou, M. Bochet, R. Tubiana, V. Thibault, L. Suffisseau, and M. Sullivan Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV N Engl J Med 348 2003 177 178
14. M. Nelson, S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, and G. Matthews An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals AIDS 17 2003 F7 F10
15. M.B. Ristig, J. Crippin, J.A. Aberg, W.G. Powderly, M. Lisker-Melman, and L. Kessels Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-co-infected individuals for whom interferon-alpha and lamivudine therapy have failed J Infect Dis 186 2002 1844 1847
16. F. Van Bömmel, T. Wunsche, D. Schurmann, and T. Berg Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication Hepatology 36 2002 507 508
17. J.E. Gallant, S. Staszewski, A.L. Pozniak, E. DeJesus, J.M. Suleiman, and M.D. Miller For the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial J Am Med Assoc 292 2004 191 201
18. G. Breton, M. Alexandre, X. Duval, D. Prie, G. Peytavin, and C. Leport Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1 Scand J Infect Dis 36 2004 527 528
19. A.B. Hansen, S. Mathiesen, and J. Gerstoft Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir Scand J Infect Dis 36 2004 389 392
20. B.S. Rifkin, and M.A. Perazella Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure Am J Med 117 2004 282 284
21. M. Saumoy, F. Vidal, J. Peraire, S. Sauleda, A.M. Vea, and C. Vilades Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 18 2004 1741 1742
22. R. Jones, J. Stebbing, M. Nelson, G. Moyle, M. Bower, and S. Mandalia Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: cohort and case-control study J Acquir Immune Defic Syndr 37 2004 1489 1495
23. S. Mauss, F. Berger, and G. Schmutz Antiretroviral therapy with tenofovir is associated with mild renal dysfunction AIDS 19 2005 93 95
24. F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, and A. Benzekri For the ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial J Am Med Assoc 292 2004 2839 2848
25. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, and K.E. Sherman For the AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-co-infected persons N Engl J Med 351 2004 451 459
26. M. Laguno, J. Murillas, J.L. Blanco, E. Martinez, R. Miquel, and J.M. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 2004 F27 F34
27. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, and A. Lazzarin For the APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
28. L. Moreno, C. Quereda, A. Moreno, M.J. Perez-Elias, A. Antela, and J.L. Casado Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients AIDS 18 2004 67 73
29. M. Pérez-Olmeda, M. Nunez, M. Romero, J. Gonzalez, A. Castro, and J.R. Arribas Pegylated interferon-α 2b+ ribavirin as therapy for chronic hepatitis C in HIV-infected patients AIDS 17 2003 1023 1028
30. M.R. Kraus, A. Schafer, H. Faller, H. Csef, and M. Scheurlen Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C Aliment Pharmacol Ther 16 2002 1091 1099
31. P.G. Hoggard, S. Kewn, M.G. Barry, S.H. Khoo, and D.J. Back Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro Antimicrob Agents Chemother 41 1997 1231 1236
32. M.W. Vogt, K.L. Hartshorn, P.A. Furman, T.C. Chou, J.A. Fyfe, and L.A. Coleman Ribavirin antagonizes the effect of azidothymidine on HIV replication Science 235 1987 1376 1379
33. A.J. Japour, J.J. Lertora, P.M. Meehan, A. Erice, J.D. Connor, and B.P. Griffith A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team J Acquir Immune Defic Syndr Hum Retrovirol 13 1996 235 246
34. V. Soriano, R. Rodriguez-Rosado, M. Perez-Olmeda, M. Romero, and J. Garcia-Samaniego Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients AIDS 14 2000 2409 2410
35. S. Mauss, W. Valenti, J. DePamphilis, F. Duff, L. Cupelli, and S. Passe Risk factors for hepatic decompensation in patients with HIV/HCV co-infection and liver cirrhosis during interferon-based therapy AIDS 18 2004 F21 F25
36. N. Brau Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C J Viral Hepat 11 2004 191 197
37. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin For the PEGASYS International Study Group: peginterferon-alpha2a and ribavirin in combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
38. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, and D.T. Dieterich For the PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
39. N.H. Afdhal, D.T. Dieterich, P.J. Pockros, E.R. Schiff, M.L. Shiffman, and M.S. Sulkowski For the Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
40. A. Landau, D. Batisse, C. Piketty, J.P. Duong Van Huyen, F. Bloch, and L. Belec Long-term efficacy of combination therapy with interferon-α 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients AIDS 15 2001 2149 2155
41. J.K. Rockstroh, M. Mudar, M. Lichterfeld, H.D. Nischalke, G. Klausen, and J. Golz For the German Clinical AIDS Working Group (KAAD). Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients AIDS 16 2002 2083 2085
42. M. Fried, M. Shiffman, R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
43. M. Manns, J. McHutchison, S. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965